LifeVantage (LFVN) 28th Annual ICR Conference 2026 summary

Product innovation and activation strategy

• Focus on 'activation' products that enhance the body's natural production of key substances, differentiating from traditional supplementation.

• Flagship product Protandim Nrf2 clinically proven to reduce oxidative stress by 40% in 30 days, supported by over 30 peer-reviewed studies.

• Product line expanded to include collagen and GLP-1 products, both designed to boost the body's own production of these substances.

• Recent acquisition of a gut microbiome company added a product that increases production of 14 gut peptides, aligning with the activation philosophy.

• All future products will adhere to the activation model, guiding the company's innovation roadmap.

Acquisition and integration of LoveBiome

• First-ever acquisition completed in October, adding a gut health product and expanding consultant and customer diversity.

• Integration executed rapidly, with full system and compensation plan alignment within a month.

• High retention rate of acquired consultants and strong cross-selling between legacy and acquired product lines.

• The gut health market is projected to grow from $8B to $32B in eight years, providing significant growth potential.

• Acquisition strategy expected to continue, with future opportunities under consideration.

Market expansion and customer base diversification

• Core revenue still driven by anti-aging product, but new launches target younger demographics and new market segments.

• Collagen and GLP-1 products opened new customer bases in beauty and weight management.

• Gut health product (P84) further diversifies the portfolio and customer reach.

• Activation philosophy unifies diverse product lines and supports expansion into new health categories.